Infancy-onset diabetes occurs within the first year of life and can be monogenic or autoimmune. We investigated insulin regimens and clinical outcomes through the U.S. Monogenic Diabetes Registry. Relevant data was extracted from medical records collected from the time of diagnosis through the first two years of life. Medical records from 67 individuals were obtained. Clinical characteristics are shown in Table 1. Insulin regimens are reported in Table 2. Most participants stayed on an insulin regimen with the same intensity, ranging from staying on a pump (CSII) to staying on 2 shots of insulin per day. While 30% increased in intensity, 14% decreased (Table 2). Many different regimens appeared to be effective in infants, but further research on greater numbers of patients may show additional advantages to more intense regimens such as CSII.
L.R. Letourneau: Other Relationship; Self; Novo Nordisk Inc. D. Carmody: Research Support; Self; Novo Nordisk Inc.. A.M. Denson: None. M. Sanyoura: None. R.N. Naylor: None. L.H. Philipson: Research Support; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Merck & Co., Inc.. Research Support; Self; JAEB Center For Health Research, JDRF, Janssen Pharmaceuticals, Inc., Medtronic MiniMed, Inc. S.W. Greeley: Research Support; Self; Novo Nordisk Inc..
